These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 3161643

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Results obtained in the treatment of prostate cancer patients with Zoladex.
    Williams G, Kerle DJ, Roe SM, Yeo T, Bloom SR.
    Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI.
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer.
    Nicholson RI, Walker KJ, Turkes A, Turkes AO, Dyas J, Blamey RW, Campbell FC, Robinson MR, Griffiths K.
    J Steroid Biochem; 1984 Jan; 20(1):129-35. PubMed ID: 6231416
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y.
    Am J Clin Oncol; 1988 Jan; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 18. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R, Borgmann V, Al-Abadi H, Schmidt-Gollwitzer M.
    J Urol (Paris); 1983 Mar 01; 89(9):669-76. PubMed ID: 6425419
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of advanced carcinoma of the prostate by LHRH-agonists.
    Claes HI, Vandenbussche L, Vereecken RL.
    Prog Clin Biol Res; 1987 Mar 01; 243A():229-37. PubMed ID: 2958853
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.